Navigation Links
Medarex Hosts June 2nd Webcast of Ipilimumab Data Presented at ASCO
Date:5/30/2008

PRINCETON, N.J., May 30 /PRNewswire-FirstCall/ -- Medarex, Inc. (Nasdaq: MEDX) is scheduled to host a webcast review of the ipilimumab data presented during the Annual Meeting of the American Society of Clinical Oncology (ASCO) in Chicago. As previously announced, the live webcast will begin at 8:00 a.m. Eastern Time / 7:00 a.m. Central Time on Monday, June 2, 2008. Medarex senior management will be joined by Jedd D. Wolchok, M.D., Ph.D., Director of Immunotherapy Clinical Trials at Memorial Sloan-Kettering Cancer Center in New York.

The webcast can be accessed on Medarex's website at http://www.medarex.com and will be archived and available for at least 14 days.

About Medarex

Medarex is a biopharmaceutical company focused on the discovery, development and potential commercialization of fully human antibody-based therapeutics to treat life-threatening and debilitating diseases, including cancer, inflammation, autoimmune disorders and infectious diseases. Medarex applies its UltiMAb(R) technology and product development and clinical manufacturing experience to generate, support and potentially commercialize a broad range of fully human antibody product candidates for itself and its partners. More than 40 of these therapeutic product candidates derived from Medarex technology are in human clinical testing or have had INDs submitted for such trials, with seven of the most advanced product candidates currently in Phase 3 clinical trials or the subject of regulatory applications for marketing authorization. Medarex is committed to building value by developing a diverse pipeline of antibody products to address the world's unmet healthcare needs. For more information about Medarex, visit its website at http://www.medarex.com.

Medarex(R), the Medarex logo and UltiMAb(R) are registered trademarks of Medarex, Inc. All rights are reserved.


'/>"/>
SOURCE Medarex, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Related medicine news :

1. Medarex Announces 2008 First Quarter Financial Results
2. Medarex and Bristol-Myers Squibb Joint Statement on Submission Status of Ipilimumab
3. Medarex Announces 2007 Fourth Quarter and Year End Financial Results
4. Medarex to Present at the Merrill Lynch Global Pharmaceutical, Biotechnology & Medical Device Conference
5. Medarex to Receive Milestone Payment for Submission of Regulatory Applications Requesting Approval of Ustekinumab (CNTO 1275) for Treatment of Psoriasis
6. PharmAthene and Medarex Announce Additional $0.8 Million U.S. Government Appropriation for Continued Development of Anthrax Therapeutic Valortim(TM)
7. Medarex to Present at the JPMorgan Small/Mid Cap Conference
8. Ono and Medarex Announce Allowance of Investigational New Drug Application for Fully Human Anti-PD1 Antibody
9. SNM hosts 55th Annual Meeting of Nuclear Medicine and Molecular Imaging Research
10. TriWest Hosts Military Heroes at National Memorial Day Parade
11. American Red Cross Hosts Heritage of Service Dinner
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/20/2017)... ... September 20, 2017 , ... “Finn Mouseson”: follows the ... in an average life. This mouse sets out on a journey that will show ... Mouseson” is the creation of newly published author and illustrator, Melody Gersonde-Mickelson, who has ...
(Date:9/20/2017)... ... September 20, 2017 , ... “Psalms of Humidity”: is ... of mind and move the readers one step closer to God. “Psalms of Humidity” ... that his mistakes that have been made within his life are the very same ...
(Date:9/20/2017)... ... ... Sang At Her Funeral”: a tale of murder that will bring a church together ... Sang At Her Funeral” is the creation of published author, Annalise Harold, an IT ... twelve grandchildren. Before becoming a writer, Annalise had the opportunity to relocate often while ...
(Date:9/19/2017)... ... September 19, 2017 , ... Only a few physicians were ... Brevard’s own Ross A. Clevens, MD, FACS . The founder and medical director ... and Reconstructive Surgeon who trained at Yale, Harvard and the University of Michigan. He ...
(Date:9/19/2017)... ... 19, 2017 , ... Trusted debt-reduction firm CreditAssociates, LLC has announced two important ... excess of $835 million in resolved debt for its clients. , Credit card debt, ... the categories of debt settled by the company. With more than a decade of ...
Breaking Medicine News(10 mins):
(Date:9/6/2017)... , Sept. 6, 2017 Eli Lilly ... it will present new data for galcanezumab and lasmiditan, ... of the International Headache Society (IHC) taking place Sept. ... Lilly will highlight new, long-term data from an ... doses of galcanezumab (120 mg and 240 mg) for ...
(Date:9/5/2017)... Pharmaceuticals Inc. (NASDAQ: ORMP ) (TASE: ORMP) ... the development of oral drug delivery systems, announced today ... U.S. Food and Drug Administration (FDA) regarding ORMD-0801, the ... At the meeting, the FDA gave clear ... would be a Biologics License Application (BLA).  Such a ...
(Date:8/29/2017)... 2017 ivWatch, LLC, the leading provider of continuous monitoring ... has been awarded an Innovative Technology contract from Vizient, Inc., the ... ... in the early detection of peripheral IV infiltration and extravasation events ... The Innovative Technology contract was awarded to ...
Breaking Medicine Technology: